Updates from companies that share news on HearingTracker
Page 29 of 44
)
Sycle, a cloud-based practice management software for the hearing healthcare industry, is expanding its relationship with Synchrony to include both the CareCredit healthcare credit card and Allegro Credit installment loan financing solutions.
)
Sony Electronics today announces the availability of its first over-the-counter (OTC) hearing aids, the CRE-C10 and the CRE-E10 self-fitting OTC hearing aids, designed with the understanding that one size does not fit all, and that people deserve options that best fit their unique needs, situations, and lives.
)
Oliver Frank, the new Vice President of Phonak Marketing, brings more than 15 years of industry experience from various local and global leadership roles within Sonova’s Hearing Instrument business.
)
Starkey has named Heinz Ruch as Chief Operations Officer, Hans Mehl as the Executive Vice President of Global Operational Excellence, and Nathanael Aguilar as Vice President of Manufacturing.
)
The second-generation device in collaboration with Bose is the first fully rechargeable hearing aid compatible with the Lexie app
)
Previously available in a limited number of states and through Walgreens.com, Lexie Lumen will be available over-the-counter (OTC) at Walgreens stores nationwide for adults ages 18 and older with mild-to-moderate hearing loss starting October 17.
)
HearUSA's new brand vision, Sound of the New Age, reflects today’s consumer commitment to live life to the fullest—no longer restricted by stigma, physical limitation, or impairment.
)
Extending the Blu line of hearing aids, Insera in-the-ear (ITE) hearing aids offer flexibility and personalization through a range of choices in size, functionality, and features based on individual needs and preferences.
)
The Alzheimer’s Association Minnesota-North Dakota announced the appointment of Michael Scholl, Compliance Officer and EVP of Corporate Relations at Starkey Hearing Technologies, to its board of directors.
)
Built on the powerful Extend platform, the new discreet hearing aids leverage more memory and greater processing power, offering next-level technology to precisely find, filter, and fine-tune the sounds users want to hear.
)
DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals and is an adeno-associated virus (AAV)-based dual-vector gene therapy designed to provide durable hearing to individuals with profound congenital hearing loss caused by mutations of the otoferlin gene.
Akouos Inc. announced it has received clearance from the FDA for its Investigational New Drug (IND) application to initiate a Phase 1/2, first in human, pediatric clinical trial of AK-OTOF, a gene therapy intended for the treatment of patients with otoferlin gene (OTOF)-mediated hearing loss.